Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development Impressive Financial Growth: The group reported a 43.5% increase in revenue, ...

GenScript is delighted to announce its 4th Annual Virtual Summit on Gene and Cell Engineering. This event will feature leading experts from academia, pharma, and biotech, showcasing the transformative ...

GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction. Legend Biotech continues to invest in R&D to expand the ...